With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.24621-61-2,(S)-Butane-1,3-diol,as a common compound, the synthetic route is as follows.
Example 4 : (R)-2-(3-{3-[[2-Chloro-3-(trifluoromethyl) benzyl] (2,2- diphenylethyl) amino]-1-methyl-propoxy}-phenyl) acetic acid methyl ester ; a) Toluene-4-sulfonic acid- (S)-3-hydroxy-butyl ester; To a stirring solution of (S)-1, 3-butanediol (1.0 g, 0.01 mmol) and triethylamine (1.39 g, 0.014 mmol) in dichloromethane (10 mL) at-20C was added dropwise p-toluenesulfonyl chloride and the mixture was stirred for 2 h. The reaction mixture was then warmed to RT and stirred overnight. The reaction mixture was poured into cold H2O (20 mL), and extracted three times with dichloromethane. The organic extracts were then washed with brine. The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo to give 2.6 g (96% yield) of title compound as an oil. MS (ESI) 244.8 (M+). The crude tosylat was used without further purification.
24621-61-2 (S)-Butane-1,3-diol 446973, achiral-oxygen-ligands compound, is more and more widely used in various.
Reference£º
Patent; SMITHKLINE BEECHAM CORPORATION; WO2003/82802; (2003); A1;,
Synthesis and Crystal Structure of a Chiral?C3-Symmetric Oxygen Tripodal Ligand and Its Applications to Asymmetric Catalysis
Chiral lanthanide(III) complexes of sulphur¨Cnitrogen¨Coxygen ligand derived from aminothiourea and sodium?D-camphor-¦Â-sulfonate